WORKSHOP DAY - MARCH 3RD
The Festival of Biologics USA will begin with an afternoon of workshops, taking place on the
3rd March from 1pm, finishing at 4pm
This workshops and panels will be on challenging topics across the antibodies, immunotherapy, clinical trials and biosimilar industries, with an additional session being run in conjunction with SDCPI, the San Diego Centre of Precision Immunotherapy.
Across the afternoon, there will be 16 workshops, as well as the SDCPI seminars, run by leading experts in their field, and are available to all fully registered attendees, speakers, sponsors and exhibitors.
13:00 - 13:45 AI for antibody drug discovery and development
An overview of how AI is currently used for in silico antibody discovery and development
Real life examples of how this is currently used, with challenges and case studies
Workshop on how AI can be implemented into the antibody industry
, Senior Principal Scientist, Bristol Myers-Squibb
, Senior Scientist, NBE Analytical R&D, AbbVie
, Senior Research Fellow, (Biotherapeutics) and Group Leader, Boehringer Ingelheim
, Principle Scientist, Lilly Biotechnology Center
14:30 - 15:15 Women in Science – panel discussion
Experiences that have influenced thinking around gender in the workplace
How companies are promoting diversity in the workplace
How can we advocate change, successes and challenges?
How can male advocates help?
, Vice President, Cell and Functional Biology, AnaptysBio
, CEO and Director of Scientific Affairs, Cancer Research Institute
, Senior Research Fellow, Protein and Antibody Engineering, Lilly Biotechnology Center
, Research Assistant, Technical University of Denmark
15:15 - 16:00 Investment in antibody therapeutics panel
Panel session lead by senior investors, actively investing within the biologics industry
What do investors look out for in start-ups?
What are the current trends for biologics?
Where do we see the industry moving to in the next 5-10 years?
How can you gain investment?
, Partner, Forward Ventures
, General Partner, Medicxi
, Managing Member, Owner, Forward Ventures
13:00 - 13:45 Progress and challenges in the design and clinical development of microbial therapies
Influence of the gut microbiome on autoimmunity
Gut microbes and immunotherapy responses
Leaky Gut Syndrome in autoimmune diseases – a potential target for therapy
Success in a probiotic trial in Irritable Bowel Syndrome – a new therapeutic perspective targeting the dysbiosis and beyond
Designing multi-targeted bacterial therapy – what tools do we need?
, CEO, ImmuneBiotech
14:00 – 16:00
A series of short presentations by members of the San Diego Center for Precision Immunotherapy
, Associate Director, U.C. San Diego Moores Cancer Center
Other SDCPI speakers TBC
13:00 - 13:45 Partnering with patient advocacy organizations to bring the patient voice into the development of clinical trials
Strategies for determining which advocacy organizations to partner with
Tactics for bringing in the patient voice early and often
Getting buy-in from Sr. leadership on the importance of advocacy relationships and inclusion of patient voice
, Director, patient Focused Drug Development, Tesaro
, Director, Corporate Affairs and Patient Advocacy, Tesaro
13:00 - 13:45 Analytics and innovation
- The role it plays in the current and future state of biosimilars
, Former Head of Technology, Cipla BioTec
13:45 - 14:30 Panel Discussion: How can we sustain the value proposition of biosimilars in the future as an industry?
, Global Head of Biogen’s Biosimilars Unit, Biogen
, Managing Director, NxR Biotechnologies GmbH
14:30 - 15:15 Implementing modern Cell engineering and Process development approaches for affordable and sustainable biosimilar manufacturing
General Overview of Biosimilars/ Biologics and opportunities for the Biopharma players
Implementation of Gene editing tools CRISPR and TALENS for cell line engineering and production improvement
Modern approaches for high producer cell line and robust upstream process development
Use of cutting edge technologies to improve biosimilar development and manufacturing
Factors influences protein expression and critical quality attributes including glycosylation of monoclonal antibodies
mAb glycosylation and its overall Impact on biosimilarity and product performance
Case studies on titer and quality improvement at clone and process level for affordable biosimilar development
, General Manager -Advanced Biotech Lab, Ipca Laboratories
14:30 - 15:15 Panel discussion: Clinical trials – do we need them to get biosimilars approved?
Clinical trials vs pharmacology studies, what does the current FDA and EU guidance say?
Clinical pharmacology studies: efficacy & safety
Q + A with the audience
, Medical Director, Oncology, Teva
, Managing Director, Cinfa Biotech
GET INVOLVED AT THE
FESTIVAL OF BIOLOGICS USA